Energy XXI Gulf Coast, Inc. (EXXI) Reaches $7.43 After 5.00% Down Move; ONCOLYTICS BIOTECH (ONCYF) Shorts Decreased By 2.42%

January 12, 2018 - By Darrin Black

ONCOLYTICS BIOTECH INCORPORATED (OTCMKTS:ONCYF) had a decrease of 2.42% in short interest. ONCYF’s SI was 301,900 shares in January as released by FINRA. Its down 2.42% from 309,400 shares previously. With 695,500 avg volume, 0 days are for ONCOLYTICS BIOTECH INCORPORATED (OTCMKTS:ONCYF)’s short sellers to cover ONCYF’s short positions. The stock increased 0.12% or $0.0009 during the last trading session, reaching $0.7615. About 189,991 shares traded. Oncolytics Biotech Inc. (OTCMKTS:ONCYF) has 0.00% since January 12, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Energy XXI Gulf Coast, Inc. (NASDAQ:EXXI) is a huge mover today! The stock decreased 0.93% or $0.07 during the last trading session, reaching $7.43. About 521,637 shares traded or 0.12% up from the average. Energy XXI Gulf Coast, Inc. (NASDAQ:EXXI) has 0.00% since January 12, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 7 months negative chart setup for the $246.84 million company. It was reported on Jan, 12 by Barchart.com. We have $7.06 PT which if reached, will make NASDAQ:EXXI worth $12.34 million less.

Energy XXI Gulf Coast, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, development, and operation of oil and natural gas properties onshore in Louisiana and Texas, and offshore in the Gulf of Mexico. The company has market cap of $246.84 million. As of December 31, 2016, it had 121.9 MMBOE of proved reserves. It currently has negative earnings.

Among 3 analysts covering Energy XXI (Bermuda) (NASDAQ:EXXI), 0 have Buy rating, 2 Sell and 1 Hold. Therefore 0 are positive. Energy XXI (Bermuda) had 7 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was downgraded by KeyBanc Capital Markets on Tuesday, December 22 to “Sector Weight”. Capital One downgraded Energy XXI Gulf Coast, Inc. (NASDAQ:EXXI) on Wednesday, September 9 to “Underweight” rating. The rating was downgraded by FBR Capital to “Underperform” on Tuesday, November 3.

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company has market cap of $106.99 million. The firm is developing REOLYSIN, a systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: